Type I interferon signaling induces a delayed antiproliferative response in respiratory epithelial cells during SARS-CoV-2 infection.

CRISPR screen SARS-CoV-2 cell proliferation interferon

Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
17 Nov 2023
Historique:
medline: 17 11 2023
pubmed: 17 11 2023
entrez: 17 11 2023
Statut: aheadofprint

Résumé

The proliferation of respiratory epithelial cells is crucial to host recovery from acute lung injury caused by SARS-CoV-2 and other viral pathogens, but the molecular pathways that govern this process are poorly understood. We performed a high-throughput CRISPR screen that surprisingly revealed a detrimental effect of specific host response, type I interferon (IFN-I) signaling, on the fitness of SARS-CoV-2-infected Calu-3 cells. While IFN-I signaling has been previously associated with several potential downstream responses, we found this effect to be primarily mediated by an inhibition of Calu-3 cellular proliferation after the early peak of SARS-CoV-2-induced cell death. Our findings provide a plausible mechanism for how sustained IFN-I signaling during SARS-CoV-2 infection might worsen lung pathology by blocking the regeneration of the alveolar epithelium from progenitor cells.

Identifiants

pubmed: 37975674
doi: 10.1128/jvi.01276-23
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0127623

Commentaires et corrections

Type : UpdateOf

Auteurs

Juliana Bragazzi Cunha (J)

Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.

Kyle Leix (K)

Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.

Emily J Sherman (EJ)

Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.

Carmen Mirabelli (C)

Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, USA.

Tristan Frum (T)

Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.

Charles J Zhang (CJ)

Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.

Andrew A Kennedy (AA)

Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.

Adam S Lauring (AS)

Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, USA.

Andrew W Tai (AW)

Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.

Jonathan Z Sexton (JZ)

Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.

Jason R Spence (JR)

Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Department of Biomedical Engineering, University of Michigan College of Engineering, Ann Arbor, Michigan, USA.

Christiane E Wobus (CE)

Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, USA.

Brian T Emmer (BT)

Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.

Classifications MeSH